A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone; Filgrastim
- Indications Multiple myeloma
- Focus Adverse reactions
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 05 May 2014 New source identified and integrated (M.D. Anderson Cancer Center; 2013-0018).
- 05 Mar 2014 Planned End Date changed from 1 Feb 2021 to 1 Mar 2021 as reported by ClinicalTrials.gov record.